Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
While T and B cell antigen receptor (TCR/BCR) signaling induces the recruitment of BCL10 bound to mucosa-associated lymphoid tissue (MALT)1 to the lymphocyte-specific CARMA1/CARD11-BCL10-MALT1 (CBM-1) signalosome, alternative CBM complexes utilize different CARMA/CARD scaffolds in distinct innate or inflammatory pathways.
|
30022982 |
2018 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We previously reported that activation of the B-cell-activating factor (BAFF) pathway upregulates nuclear factor-κB (NF-κB) and induces BCL3 and BCL10 nuclear translocation in Helicobacter pylori (HP)-independent gastric diffuse large B-cell lymphoma (DLBCL) tumours with evidence of mucosa-associated lymphoid tissue (MALT).
|
27873317 |
2017 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Similarly, the three MALT lymphoma associated chromosome translocations, namely t(1;14)(p22;q32)/BCL10-IGH, t(14;18)(q32;q21)/IGH-MALT1,and t(11;18)(q21;q21)/BIRC3 (API2)-MALT1, are also capable of activating both canonical and non-canonical NF-κB pathways.
|
27452667 |
2016 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
FusionGene
|
disease |
ORPHANET |
Molecular Pathogenesis of MALT Lymphoma.
|
25922601 |
2015 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our series revealed t(14;18) (q32;q21) in 6/43 cases (14,3%). t(1;14) (p22;q32), never described in ocular adnexa MALT lymphomas, was observed in 3/31 (9,7%), two of which exhibited the gain of 3' upstream BCL10 gene signal (4%), whereas no case showed t(11;18) (q21;q21).
|
23846624 |
2014 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We investigated the expression of Bcl10 gene mutations in mucosa-associated lymphoid tissue-type ocular adnexal lymphoma (OAL), atypical lymphoid hyperplasia (ALH), and reactive lymphoid hyperplasia (RLH) in the Chinese population and its role in clinical diagnosis and pathogenesis.
|
23661444 |
2013 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Both t(11;18)(q21;q21)-positive MALT lymphoma cases and those with nuclear BCL10 expression are considered resistant to H. pylori eradication.
|
22363141 |
2012 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Few cases of breast MALT lymphomas in the literature have been assessed for MALT lymphoma-associated translocations and BCL10 expression, underlying their rarity in primary breast MALT lymphomas.
|
22842723 |
2012 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Translocations involving BCL10 in the mucosa-associated lymphoid tissue (MALT) lymphomas are associated with constitutive activation of NF-κB.
|
22579587 |
2012 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Mucosa-associated lymphoid tissue (MALT) lymphoma is characterized by t(11;18)(q21;q21)/API2-MALT1, t(1;14)(p22;q32)/BCL10-IGH and t(14;18)(q32;q21)/IGH-MALT1, which commonly activate the nuclear factor (NF)-kappaB pathway.
|
20520640 |
2010 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
As we observed MALT1-API2 to be an efficient target of its own E3 ubiquitin ligase activity, our data suggest that this inherent instability of MALT1-API2 prevents its accumulation and renders a potential effect on MALT lymphoma development via destabilization of BCL10 unlikely.
|
19279678 |
2009 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
BCL10, required for nuclear factor kappaB (NF-kappaB) activation during antigen-driven lymphocyte responses, is aberrantly expressed in mucosa-associated lymphoid tissue-type marginal zone (MZ) lymphomas because of chromosomal translocations.
|
19696203 |
2009 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We investigated the efficacy of H. pylori eradication and assessed the predictive value of BCL10 nuclear expression and t(11;18)(q21;q21) regarding resistance to H. pylori eradication in primary gastric mucosa-associated lymphoid tissue lymphoma (MALT lymphoma) patients from mainland China.
|
18949449 |
2008 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Translocations involving IGH were detected in 36 (32%) of 111 cases; their partner genes included BCL6 (n = 10), c-MYC (n = 5), and FOXP1 (n = 3) but remained unknown in the remaining 18 cases. t(14;18)/IGH-BCL2, t(14;18)/IGH-MALT1, and t(1;14)/BCL10-IGH were not detected in any case. t(11;18)/API2-MALT1 was detected in none of the cases, except for one case of DLBCL with MALT lymphoma, which showed positive signals only in MALT lymphoma cells.
|
18445693 |
2008 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
We assessed the incidence and clinical significance of the MALT lymphoma-associated genetic abnormalities t(11;18)/API2-MALT1, t(1;14)/BCL10-IGH, t(14;18)/IGH-MALT1, t(3;14)/FOXP1-IGH, and extra copies of MALT1 and FOXP1 in gastric MALT lymphomas from Japan.
|
17525089 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Our results showed five key findings, which are (a) higher detection rates of t(11;18) (21.13%) in Chinese patients with transformed MALT lymphoma, (b) lower detection rates of t(11;18) in stomach MALT lymphoma, (c) different organ localizations of MALT lymphoma in Chinese patients, (d) higher nuclear expression rates of Bcl-10 in low grade MALT (51.72%), and (e) lower response rates (50% CR, and 50% PR) to anti-H.-pylori therapy.
|
17852708 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
LHGDN |
Nuclear expression of bcl-10 is seen mainly in MALT lymphoma, especially when occurring in ocular adnexa and lung.
|
18346354 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Further, all four patients with differential response of MALToma and DLBCL to HPET showed nuclear expression of BCL10 in the H. pylori-independent component and cytoplasmic expression of BCL10 in the H. pylori-dependent component while the expression patterns of BCL10 were identical in both of these components in the 14 patients who had similar tumour response to HPET.
|
17167822 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
AlteredExpression
|
disease |
BEFREE |
Bcl10 is a caspase-recruitment domain-containing protein, associated with constitutive activation of NF-kappaB in MALT (mucosa-associated lymphoid tissue) lymphomas.
|
17540779 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
AlteredExpression
|
disease |
LHGDN |
MALT1, BCL10 and FOXP1 in salivary gland mucosa-associated lymphoid tissue lymphomas.
|
17199743 |
2007 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
We have recently shown that nuclear translocation of Bcl10 is a specific molecular determinant of Helicobacter pylori-independent mucosa-associated lymphoid tissue lymphoma (Kuo, S.-H., Chen, L. T., Yeh, K.-H., Wu, M. S., Hsu, H. C., Yeh, P. Y., Mao, T. L., Chen, C. L., Doong, S. L., Lin, J. T., and Cheng, A.-L. (2004) J. Clin.Oncol.22, 3491-3497).
|
16280327 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
GeneticVariation
|
disease |
BEFREE |
Apoptosis regulator B-cell lymphoma 10 (BCL10) may show aberrant nuclear localization in some aggressive extracutaneous MALT lymphomas, often in association with a MALT1 gene t(11;18)(q21;q21) translocation.
|
16784987 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Here we show that cIAP2 is a ubiquitin ligase (E3) of BCL10 and targets it for degradation, inhibiting antigen receptor-mediated cytokine production. cIAP2-MALT1 lacks E3 activity, and concomitantly, the BCL10 protein is stabilized in MALT lymphomas harboring this fusion.
|
16395405 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
LHGDN |
This study further supports the close interaction between the MALT1 and BCL10 proteins in the pathogenesis of MALT lymphomas and may indicate that BCL10 immunohistochemistry is a simple technique to identify those MALT lymphoma cases with an underlying genetic aberration.
|
16341151 |
2006 |
Mucosa-Associated Lymphoid Tissue Lymphoma
|
0.800 |
Biomarker
|
disease |
BEFREE |
Weak cytoplasmic BCL-10 staining in most cases and evidence of NF-kappaB p50 activation in a subset differs from breast MALT lymphomas.
|
16917511 |
2006 |